Immunological treatment of ovarian cancer

Current Opinion in Obstetrics and Gynecology

Volumn 16, Issue 1, 2004, Pages 87-92

  Cannon, Martin J ^a   Santin, Alessandro D ^b   O'Brien, Timothy J ^b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

CA125; Dendritic cells; Immunotherapy; Ovarian cancer; Vaccination

Indexed keywords

ANTINEOPLASTIC AGENT; CA 125 ANTIGEN; CANCER VACCINE; CARBOHYDRATE ANTIGEN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEPSIN; IDIOTYPIC ANTIBODY; KALLIKREIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY C MOV18; MUCIN 1; MURINE MONOCLONAL ANTIBODY B43.13; MURINE MONOCLONAL IDIOTYPIC ANTIBODY ACA125; NEUROPSIN; PACLITAXEL; PEPTIDE; PROTEIN P53; SERINE PROTEINASE; SIALYL TN KEYHOLE LIMPET HEMOCYANIN CONJUGATE VACCINE; STRATUM CORNEUM CHYMOTRYPTIC ENZYME; TESTISIN; THERATOPE; TRASTUZUMAB; TUMOR ANTIGEN; TUMOR ASSOCIATED DIFFERENTIALLY EXPRESSED GENE PRODUCT 12; TUMOR ASSOCIATED DIFFERENTIALLY EXPRESSED GENE PRODUCT 14; TUMOR ASSOCIATED DIFFERENTIALLY EXPRESSED GENE PRODUCT 15; TUMOR ASSOCIATED DIFFERENTIALLY EXPRESSED GENE PRODUCT 16; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; AMINO ACID SEQUENCE; ANTIBODY RESPONSE; ANTIGEN STRUCTURE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CANCER STAGING; CANCER SURVIVAL; CELLULAR IMMUNITY; CLINICAL TRIAL; CORRELATION ANALYSIS; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG EFFICACY; DRUG TARGETING; DRUG TOXICITY; GENE OVEREXPRESSION; HUMAN; IMMUNOMODULATION; LUNG NON SMALL CELL CANCER; MOLECULAR CLONING; OVARY CANCER; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; TREATMENT OUTCOME; VACCINATION;

DENDRITIC CELLS; FEMALE; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOTHERAPY; OVARIAN NEOPLASMS; PROTEINS; VACCINATION; VACCINES, SUBUNIT;

EID: 1242294500     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001703-200402000-00015     Document Type: Review

References (32)

1. Holmberg LA, Oparin DV, Gooley T, Sandmaier BM. The role of cancer vaccines following autologous stem cell rescue in breast and ovarian cancer patients: experience with the STn-KLH vaccine (Theratope®). Clin Breast Cancer 2003; 3:S144-S151. This report describes antibody and cellular responses to STn-KLH vaccination following high-dose chemotherapy and stem cell rescue.
2. Anonymous. Biomira and Merck KgaA announce phase III Theratope® vaccine does not meet primary endpoints - trend to improvement in survival seen in subset of patients. June 16, 2003, www.biomira.com. Recently announced results from a multicenter phase III clinical trial of Theratope in patients with metastatic breast cancer indicated that this trial did not meet predetermined endpoints regarding disease progression and overall survival (posted 16 June 2003 on the sponsors' website).
3. Mobus VJ, Baum RP, Bolle M, et al. Immune responses to murine monoclonal antibody-B43.13 correlate with prolonged survival of women with recurrent ovarian cancer. Am J Obstet Gynecol 2003; 189:28-36. This paper describes a clinical trial with a CA125-specific mouse MAb in patients with advanced stage ovarian cancer. The authors report a strong correlation between human anti-mouse antibody responses and improvement in overall survival (22.6 months in responders versus 7.2 months in nonresponders).
4. Wagner U, Kohler S, Reinartz S, et al. Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment. Clin Cancer Res 2001; 7:1154-1162.
5. Van Zanten-Przybysz I, Molthoff C, Gebbinck JK, et al. Cellular and humoral responses after multiple injections of unconjugated chimeric monoclonal antibody MOv18 in ovarian cancer patients: a pilot study. J Cancer Res Clin Oncol 2002; 128:484-492.
6. Knutson KL, Disis ML. Clonal diversity of the T-cell population responding to a dominant HLA-A2 epitope of HER-2/neu after active immunization in an ovarian cancer patient. Hum Immunol 2002; 63:547-557. This paper describes the diversity of T-cell responses in an ovarian cancer patient vaccinated with HER2/neu peptides that incorporate both helper T-cell and CTL epitopes.
7. Disis ML, Gooley TA, Rinn K, et al. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol 2002; 20:2624-2632. An important paper describing the immunogenicity of HER2/neu peptide vaccination in patients with stage III or stage IV ovarian, breast, or non-small cell lung cancer: a notable finding is that the majority of vaccinees showed evidence of epitope spreading, that is an immune response to epitopes other than those present in the vaccine formulation.
8. + T-cell immunity in cancer patients. J Clin Invest 2001; 107:477-484.
9. + helper T cell epitopes and CTL epitopes (see Ref. [8]).
10. Schlienger K, Chu CS, Woo EY, et al. TRANCE-and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients. Clin Cancer Res 2003; 9:1517-1527. This study uses a novel technique for dendritic cell maturation, and supports earlier reports that tumor antigen-pulsed dendritic cells can stimulate CTL responses against autologous ovarian tumor cells (see Refs [11-13]).
11. + cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer. Am J Obstet Gynecol 2000; 183:601-609.
12. + cytotoxic T lymphocytes by acid-eluted peptide-pulsed autologous dendritic cells. Obstet Gynecol 2000; 96:422-430.
13. Zhao X, Wei YQ, Peng ZL. Induction of T cell responses against autologous ovarian tumors with whole tumor cell lysate-pulsed dendritic cells. Immunol Invest 2001; 30:33-45.
14. Nestlé FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide or tumor lysate-pulsed dendritic cells. Nat Med 1998; 4:328-332.
15. Brossart P, Wirths S, Stuhler G, et al. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 2000; 96:3102-3108.
16. Cannon MJ, O'Brien TJ, Underwood LJ, et al. Novel target antigens for dendritic cell-based immunotherapy against ovarian cancer. Exp Rev Anticancer Therapy 2002; 2:97-105. This review provides a comprehensive account of an important series of novel serine protease and matrix metalloprotease antigens overexpressed by ovarian tumors.
17. Duan Z, Duan Y, Lamendola DE, et al. Overexpression of MAGE/GAGE genes in paclitaxel/doxorubicin-resistant human cancer cell lines. Clin Cancer Res 2003; 9:2778-2785. A remarkable study showing that MAGE and GAGE antigens are overexpressed by drug-resistant ovarian tumor cells, and that these antigens may play a role in the drug-resistant phenotype. These results also point to MAGE and GAGE as potential target antigens for immunotherapy of ovarian cancer.
18. Stone B, Schummer M, Paley PJ, et al. Serologic analysis of ovarian tumor antigens reveals a bias towards antigens encoded on 17q. Int J Cancer 2003; 104:73-84. An important study that illustrates the power of SEREX analysis for identification of immunogenic tumor antigens.
19. O'Brien TJ, Beard JB, Underwood LJ, et al. The CA125 gene: an extracellular superstructure dominated by repeat sequences. Tumour Biol 2001; 22:348-366.
20. Yin BWT, Lloyd KO. Molecular cloning of the CA125 ovarian cancer antigen. J Biol Chem 2001; 276:27371-27375.
21. O'Brien TJ, Beard JB, Underwood LJ, Shigemasa K. The CA125 gene: a newly discovered extension of the glycosylated N-terminal domain doubles the size of this extracellular superstructure. Tumour Biol 2002; 23:154-169. The latest, and most probably definitive, report on the sequence and protein backbone of CA125, following two other major reports on cloning and sequencing of CA125 (Refs [19,20]).
22. Kui Wong N, Easton RL, Panico M, et al. Characterization of the oligosaccharides associated with the human ovarian tumor marker CA125. J Biol Chem 2003; 278:28619-28634. A comprehensive and highly detailed analysis of carbohydrate structures on CA125. This study highlights potential structure-function relationships, including a proposed role of CA125 in modulation of natural killer and T-cell function.
23. El Ouagari K, Teissié J, Benoist H. Glycophorin A protects K562 cells from natural killer cell attack. J Biol Chem 1995; 270:26970-26975.
24. Mitchell DA, Fadden AJ, Drickamer K. A novel mechanism of carbohydrate recognition by the C-type lectins DC-SIGN and DC-SIGNR. J Biol Chem 2001; 276:28939-28945.
25. x glycan (also present on CA125) binds DC-SIGN expressed on dendritic cells.
26. Van Kooyk Y, Geijtenbeek TBH. A novel adhesion pathway that regulates dendritic cell trafficking and T cell interactions. Immunol Rev 2002; 186:47-56. This review provides a comprehensive account of the role of the C-type lectin DC-SIGN in dendritic cell trafficking and T-cell interactions.
27. Geijtenbeek TB, Van Vliet SJ, Koppel EA, et al. Mycobactena target DC SIGN to suppress dendritic cell function. J Exp Med 2003; 197:7-17. The mycobacterial mannose-based oligosaccharide lipoarabinomannan binds to DC-SIGN (which specifically interacts with α-D-mannoses) and blocks dendritic cell maturation. This is important in the context of ovarian cancer because the N-terminus of CA125 is rich in high mannose N-glycans, suggesting a possible mechanism for CA125 to subvert dendritic cell function and ovarian tumor-specific immune responses.
28. Sellenmeyer C, Wegehingel S, Lechner J, Nickel W. The cancer antigen CA125 represents a novel counter receptor for galectin-1. J Cell Sci 2003; 116:1305-1318. CA125 binds galectin-1, and may play a key role as a chaperone for cell surface expression of galectin-1. This is a high impact report, because galectin-1 is well known for its ability to induce apoptosis in activated T cells (see Refs [29-31]).
29. Vespa GN, Lewis LA, Kozak KR, et al. Galectin-1 specifically modulates TCR signals to enhance TCR apoptosis but inhibit IL-2 production and proliferation. J Immunol 1999; 162:799-806.
30. Pace KE, Hahn HP, Pang M et al. CD7 delivers a pro-apoptotic signal during galectin-1-induced cell death. J Immunol 2000; 165:2331-2334.
31. Nguyen JT, Evans DP, Galvan M, et al. CD45 modulates galectin-1-induced T cell death: regulation by expression of core 2 O-glycans. J Immunol 2001; 167:5697-5707.
32. Schuler G, Schuler-Thumer B, Steinman RM. The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol 2003; 15:138-147. A thorough account of dendritic cell technology and tumor immunotherapy. The authors appreciate the challenges of dendritic cell-based vaccination, but offer a strong advocacy of this approach.